2026 ICD-10-CM Diagnosis Code T39.4X5SAdverse effect of antirheumatics, not elsewhere classified, sequela

ICD-10-CM Codes›S00–T88›T36-T50›T39

ICD-10-CM T39.4X5S
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T39.4X5S is a billable ICD-10-CM diagnosis code for adverse effect of antirheumatics, not elsewhere classified, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. Coders also document this condition as abnormal vasomotor function. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.

Code Identity

ICD-10-CM Code
T39.4X5S
Billable Status
Yes — Valid for Submission
Code Describes
Adverse effect of antirheumatics, not elsewhere classified, sequela
Short Description
Adverse effect of antirheumatics, NEC, sequela
Parent Code
T39.4X5
Adverse effect of antirheumatics, not elsewhere classified

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT39Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics
This CodeT39.4X5SAdverse effect of antirheumatics, not elsewhere classified, sequela

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T39.4X5S.

Unacceptable principal diagnosis
There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)Billing

T39.4X5S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Abnormal vasomotor function
  • Adverse reaction to antirheumatic
  • Adverse reaction to gold and/or gold compound
  • Adverse reaction to sodium aurothiomalate
  • Adverse reaction to tocilizumab
  • Auranofin adverse reaction
  • Chrysoderma
  • Nitritoid reaction

Coding GuidelinesGuidance

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics (T39). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ075
Poisoning/toxic effect/adverse effects/underdosing, sequela
Default principal diagnosis: inpatient No · outpatient Yes

Clinical InformationClinical

  • Auranofin

    an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.

  • Aurothioglucose

    a thioglucose derivative used as an antirheumatic and experimentally to produce obesity in animals.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect		Under­dosing
Antiphlogistic NECT39.4X1T39.4X2T39.4X3T39.4X4T39.4X5T39.4X6
Antirheumatic NECT39.4X1T39.4X2T39.4X3T39.4X4T39.4X5T39.4X6
AuranofinT39.4X1T39.4X2T39.4X3T39.4X4T39.4X5T39.4X6
AurothioglucoseT39.4X1T39.4X2T39.4X3T39.4X4T39.4X5T39.4X6
AurothioglycanideT39.4X1T39.4X2T39.4X3T39.4X4T39.4X5T39.4X6
Aurothiomalate sodiumT39.4X1T39.4X2T39.4X3T39.4X4T39.4X5T39.4X6
AurotioprolT39.4X1T39.4X2T39.4X3T39.4X4T39.4X5T39.4X6
Glucosamine sulfateT39.4X1T39.4X2T39.4X3T39.4X4T39.4X5T39.4X6

Patient EducationClinical

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

  • What is a drug interaction?
  • What are side effects?
  • What are drug allergies?
  • How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T39.4X5S to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
909.5 Lte efct advrs efct drug
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E935.6 Adv eff antirheumatics
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T39.4X5SOverview

Is T39.4X5S (Adverse effect of antirheumatics, not elsewhere classified) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of antirheumatics, not elsewhere classified, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character S in T39.4X5S mean?

The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of antirheumatics, not elsewhere classified itself has resolved, not the original event.

What MS-DRG does T39.4X5S group to?

On inpatient claims, adverse effect of antirheumatics, not elsewhere classified, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.

Can T39.4X5S be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of antirheumatics, not elsewhere classified, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Is T39.4X5S exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of antirheumatics, not elsewhere classified, sequela on inpatient claims.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.